[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349972-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349972-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","kat2b-mediated-epigenetic-suppression-of-rad51c-enhances-olaparib-sensitivity-in-colorectal-cancer","KAT2B-mediated epigenetic suppression of RAD51C enhances olaparib sensitivity in colorectal cancer","","Olaparib suppresses tumor proliferation by blocking PARP and limiting DNA damage repair, yet some colorectal cancer (CRC) patients receiving monotherapy show poor repair capability and still resist PARPi treatment. RAD51C reversion mutations frequently drive PARP inhibitor resistance in BRCA-mutated contexts. This study introduces KAT2B as a transcription-related regulator of RAD51C, lowering RAD51C expression through reduced histone H3 acetylation (H3K27ac) at its promoter. Tumor subpopulations with reduced KAT2B/RAD51C accumulate more DNA damage (γH2AX), display diminished PARPi resistance, and become more vulnerable to olaparib, supporting KAT2B- and histone-acetylation-dependent PARPi response control.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/kat2b-mediated-epigenetic-suppression-of-rad51c-enhances-olaparib-sensitivity-in-colorectal-cancer/349972/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/kat2b-mediated-epigenetic-suppression-of-rad51c-enhances-olaparib-sensitivity-in-colorectal-cancer/349972.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is olaparib effective for tumors, and why does resistance occur in colorectal cancer?","Question",{"text":63,"@type":64},"Olaparib inhibits PARP, reducing DNA damage repair and thereby decreasing tumor proliferation. Resistance in CRC can arise when cancer cells retain or regain DNA repair capacity, with RAD51C reversion mutations highlighted as a frequent driver of PARP inhibitor resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does KAT2B affect RAD51C expression and DNA damage?",{"text":68,"@type":64},"KAT2B regulates RAD51C transcription by reducing acetylation of histone H3 (H3K27) at the RAD51C promoter. Reduced KAT2B/RAD51C increases DNA damage accumulation, indicated by higher γH2AX levels.",{"name":70,"@type":61,"acceptedAnswer":71},"What do the results indicate about PARPi sensitivity in CRC?",{"text":72,"@type":64},"CRC cells with lower KAT2B and RAD51C levels are more vulnerable to olaparib. The study concludes that PARPi responses and RAD51C expression are significantly regulated by KAT2B and histone acetylation, particularly in resistant scenarios.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349972,1790861215,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Cancer Chemotherapy and Pharmacology (2026) 96:27  \n[https://doi.org/10.1007/s00280-026-04872-2](https://doi.org/10.1007/s00280-026-04872-2)  \nORIGINAL ARTICLE  \nKAT2B-mediated epigenetic suppression of RAD51C enhancesolaparib sensitivity in colorectal cancer  \nXiaoqin Liu2 · Jun Chen3 · Xuwei Shen1 · Lin Li1  \nReceived: 23 September 2025 / Accepted: 19 February 2026 © The Author(s) 2026  \nAbstract  \nIntroduction By blocking poly ADP ribose polymerase (PARP), olaparib decreases the proliferation of tumours by preventing DNA damage repair, particularly in tumours that have BRCA1/2 mutations or are BRCA-negative. However, a phase II study of 33 CRC patients receiving mono-olaparib therapy revealed that some of these individuals still had resistance toolaparib therapy but had poor DNA damage repair ability. RAD51C reversion mutation is a frequent reason for the resistance of cancers with BRCA mutations to PARP inhibitors.  \nMethods Here, we introduce K(lysine)-acetyltransferase 2B (KAT2B) as a protein involved in the transcription of RAD51C, reducing the expression of RAD51C by lowering the acetylation of histone H3 (H3K27) at the promoter of RAD51C. Results We found that a subset of tumour cells expressing RAD51C presented reduced endogenous KAT2B expression, which led to increased accumulation of DNA damage (increased γH2AX accumulation), and lower KA2TB expression decreased PARPi resistance in RAD51C-expressing cells. These findings indicate that colorectal cancer cells with lower KAT2B and RAD51C levels are more vulnerable to olaparib therapy. Our findings indicate that PARPi responses and the expression of RAD51C are significantly regulated by KAT2B and histone acetylation.  \nConclusion These results offer vital and novel insights into the combination of inhibitors in patients who are resistant toolaparib therapy, especially patients with RAD51C reversion mutations.  \nKeywords RAD51C · KAT2B · H3K27ac · γH2AX · DNA damage · Homologous recombination repair · Colorectal  \ncancer  \nIntroduction  \nAdvancements in treatment options for colorectal cancer (CRC) have been made with the introduction of antiangiogenic drugs, triplet chemotherapy regimens based on fluoropyrimidine, and targeted therapy for epidermal growth factor receptor (EGFR) via irinotecan [1] . These advancements have positively impacted the survival rates of those with CRC, but they have resulted in a slow evolution rather  \n􀀍 Lin Li[ll.666999111000@gmail.com](ll.666999111000@gmail.com)  \n1 Department of Vascular Surgery, Xiamen Cardiovascular Hospital Xiamen University, Xiamen, China  \n2 Department of Gastroenterology, Jingning People’s Hospital, Lishui, JingNing, China  \n3 Department of Emergency, Nanjing First Hospital, Nanjing Medical University, Nanjing, China  \nthan a reformative transformation in the way CRC is treated [2] . Therefore, finding a method to improve disease management in individuals with CRC is crucial for increasing their chances of survival.  \nSubsets of colorectal cancer (CRC) patients with deficiencies in DNA repair mechanisms have been identified by analysing extensive CRC datasets at the molecular level. Certain patients could benefit from specific treatment approaches. Inherited pathogenic mutations in the breast cancer type 1 susceptibility protein (BRCA1) have been associated with CRC [3], especially in patients who are young [4], due to the malfunction of the homologous recombination (HR) repair pathway [5–7] . New studies have shown that up to 15% of individuals with cancer have genetic mutations in genes related to HR repair, which can be either inherited or acquired [8–10] . Certain types of cancer can be targeted by particular DNA-damaging drugs, such as platinum compounds and PARP inhibitors (PARPis)[11–13] .  \n1 3  \nOlaparib is used to treat breast, ovarian, fallopian tube, peritoneal, pancreatic, and prostate cancer [11, 14] . The progress of the use of PARP inhibitors (PARPis) in treating colorectal cancers (CRCs) has been i","cbCaimE5LguaOSXf","https://ap.wps.com/l/cbCaimE5LguaOSXf","pdf",3197728,18,"English","# Introduction\n## PARP inhibitors and olaparib resistance in CRC\n## DNA repair, BRCA1/2, and RAD51C reversion\n## Histone acetylation, BRD proteins, and KAT2B rationale\n# Methods\n# Results\n# Conclusion","[{\"question\":\"Why is olaparib effective for tumors, and why does resistance occur in colorectal cancer?\",\"answer\":\"Olaparib inhibits PARP, reducing DNA damage repair and thereby decreasing tumor proliferation. Resistance in CRC can arise when cancer cells retain or regain DNA repair capacity, with RAD51C reversion mutations highlighted as a frequent driver of PARP inhibitor resistance.\"},{\"question\":\"How does KAT2B affect RAD51C expression and DNA damage?\",\"answer\":\"KAT2B regulates RAD51C transcription by reducing acetylation of histone H3 (H3K27) at the RAD51C promoter. Reduced KAT2B/RAD51C increases DNA damage accumulation, indicated by higher γH2AX levels.\"},{\"question\":\"What do the results indicate about PARPi sensitivity in CRC?\",\"answer\":\"CRC cells with lower KAT2B and RAD51C levels are more vulnerable to olaparib. The study concludes that PARPi responses and RAD51C expression are significantly regulated by KAT2B and histone acetylation, particularly in resistant scenarios.\"}]","KAT2B-mediated epigenetic suppression of RAD51C enhances olaparib sensitivity in colorectal cancer | PDF",1790086529,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1026f64dc73347fc0afdf1997d2dcf06.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6118338c69828a91adcc4e5b5a3d2d46.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/000af54e49ca86772546a35723dec540.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7099df81143cf7639ec509a2af6ff73b.webp",980,1301]